The insurance trust fund for the Miami police officers’ union has brought a class action suit against AstraZeneca, maker of Nexium, and the manufacturers of generic versions of that drug alleging that the pharmaceutical giant paid the generic companies to keep their drugs off the market.
The plaintiffs allege that the so-called “pay-to-delay” payments resulted in their having to pay higher costs for prescriptions for Nexium.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
